Nanozyme-based therapeutic strategies for traumatic brain injury Authors: Yi Ma, Xialio Tan, Xinyue Chen, Hongbin Zang, Zhe Li, Xin Deng, Jinqu Hu Published: 2026 ABSTRACT Traumatic brain injury (TBI) is a leading cause of mortality and long-term neurological disability worldwide. Secondary injury, characterized by oxidative stress, neuroinflammation, blood brain barrier dysfunction, and lipid peroxidation, plays a crucial role in the progression of neurological damage following the initial mechanical insult. Despite substantial advances in clinical management, current therapeutic strategies remain largely supportive and have shown limited efficacy in preventing the complex pathological cascades associated with secondary brain injury. Nanozymes, a class of nanomaterials with intrinsic enzyme mimicking catalytic activities, have emerged as promising candidates for TBI therapy owing to their high stability, tunable catalytic performance, and sustained antioxidant capacity. Increasing evidence indicates that nanozymes can restore redox homeostasis, alleviate neuroinflammation, protect neurovascular integrity, and regulate lipid peroxidation related pathways. Representative preclinical studies have reported measurable benefits, including improved 30-day survival from 50% to 90% with oligomeric carbon nanozymes, preservation of post-traumatic cerebral perfusion by PEGylated oxidized activated charcoal nanozymes, and reduction of the ischemic area from 153 mm2 to 36 mm2 after repeated treatment with NIR-IIb fluorescent nanozymes. This review summarizes the pathological basis for nanozyme intervention in TBI, recent advances in nanozyme based therapeutic strategies, and the major challenges associated with clinical translation. Future perspectives on mechanism oriented catalytic nanomedicine for TBI treatment are also discussed. Introduction Traumatic brain injury (TBI) is a major cause of death and long-term neurological disability worldwide (Baracaldo-Santamaría et al., 2022; Cancelliere et al., 2023; Costello and Greenwald, 2022; El Baassiri et al., 2024). Despite substantial advances in neurosurgical techniques, intensive care management, and neurocritical monitoring, effective pharmacological interventions remain limited (Clark et al., 2022; Fesharaki-Zadeh and Datta, 2024; Gil-Jardiné et al., 2023). The pathological progression of TBI is commonly divided into primary injury and secondary injury. Primary injury occurs immediately after mechanical trauma and is generally considered irreversible (Dams-O'Connor et al., 2023; Kalra et al., 2022; Korley et al., 2022; Li et al., 2023a). In contrast, secondary injury evolves over a prolonged period following the initial insult and contributes substantially to progressive neuronal loss and neurological dysfunction. Therefore, therapeutic strategies aimed at limiting secondary injury have become a major focus of current TBI research. Among the pathological processes involved in secondary injury, oxidative stress is widely recognized as a central contributor to disease progression (Izzy et al., 2023; Joyce et al., 2022; Kim et al., 2023; Maas et al., 2022a). Mechanical trauma disrupts cellular homeostasis and induces mitochondrial dysfunction, calcium overload, and excitotoxicity, leading to excessive production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) (Ai et al., 2023; Alwisi et al., 2026; Athavale et al., 2025). The accumulation of these reactive species causes lipid peroxidation, protein oxidation, DNA damage, and impairment of blood brain barrier integrity (Jha et al., 2024; Khalili et al., 2023; Maas et al., 2022b). Moreover, oxidative stress interacts closely with neuroinflammation, ferroptosis, and mitochondrial dysfunction, thereby creating a vicious cycle that amplifies tissue damage. Growing evidence suggests that restoring redox homeostasis may represent an effective approach for mitigating neurological deficits following TBI (Johnson and Diaz, 2023; Machamer et al., 2022; Manley et al., 2025). Considerable efforts have been devoted to the development of antioxidant therapies for TBI (Khayatan et al., 2022; Meyfroidt et al., 2022; Orr et al., 2024). However, the clinical efficacy of conventional antioxidants has been disappointing because of their poor stability, rapid clearance, insufficient catalytic capacity, and limited accumulation within injured brain tissues (Zhang et al., 2024a; Mohsin et al., 2025; Lin, 2024). Nanozymes, a class of nanomaterials that possess intrinsic enzyme mimicking catalytic activities, have recently emerged as promising candidates for the treatment of oxidative stress related diseases (Mohammed et al., 2023; Zhang et al., 2025a; Zheng et al., 2024a; Jeyachandran et al., 2023). Unlike traditional antioxidants that are consumed during redox reactions, nanozymes can continuously catalyze the conversion of reactive species into less harmful products. Depending on their composition and structure, nanozymes may exhibit activities similar to superoxide dismutase, catalase, glutathione peroxidase, or multiple antioxidant enzymes simultaneously (Tarudji et al., 2023; Xu et al., 2025; Zhang et al., 2025b). Recent advances in nanotechnology have further enabled the rational design of nanozymes with improved catalytic efficiency, enhanced biocompatibility, imaging capability, and increased accumulation within pathological tissues (Gao et al., 2023; Chen et al., 2025; Zandieh and Liu, 2022). In this review, we summarize recent progress in the application of nanozymes for TBI therapy. We first discuss the pathological basis that supports the use of nanozymes in the treatment of secondary brain injury. Subsequently, representative nanozyme platforms are categorized into carbon based nanozymes, metal based nanozymes, semiconductor nanozymes, and metal nitrogen carbon nanozymes. Their catalytic mechanisms, biological functions, and therapeutic performance in experimental models of TBI are critically discussed. Finally, current challenges and future opportunities are highlighted, with particular emphasis on blood brain barrier penetration, biosafety, large scale manufacturing, and mechanism oriented nanozyme design. To improve structural clarity, current translational challenges and future design perspectives are discussed in separate sections. This review aims to provide a comprehensive perspective on the development of catalytic nanomedicine for TBI and other neurological disorders associated with oxidative stress. (Fig. 1).Fig. 1Representative nanozyme platforms and their enzyme-like catalytic activities for traumatic brain injury therapy. Different nanozymes exhibit superoxide dismutase-like, catalase-like, and glutathione peroxidase-like activities, providing catalytic antioxidant effects and neuroprotection in traumatic brain injury.Fig. 1 Representative nanozyme platforms and their enzyme-like catalytic activities for traumatic brain injury therapy. Different nanozymes exhibit superoxide dismutase-like, catalase-like, and glutathione peroxidase-like activities, providing catalytic antioxidant effects and neuroprotection in traumatic brain injury. Pathological Basis for nanozyme therapy in TBI Oxidative stress and redox imbalance Oxidative stress is one of the earliest and most important pathological events during secondary brain injury after TBI (Lavinio et al., 2024; Madhok et al., 2022; Payen et al., 2023). Following mechanical trauma, mitochondrial dysfunction, excitotoxicity, calcium overload, and impaired cerebral perfusion collectively disturb redox homeostasis in neurons, glial cells, and vascular endothelial cells. These changes lead to excessive generation of reactive oxygen species and reactive nitrogen species, including superoxide anion, hydrogen peroxide, hydroxyl radical, nitric oxide, and peroxynitrite (Lennon et al., 2023). Under physiological conditions, endogenous antioxidant systems such as superoxide dismutase, catalase, glutathione peroxidase, and glutathione maintain a dynamic balance between oxidant production and elimination. However, after TBI, the rapid and persistent production of reactive species overwhelms these defense systems, resulting in widespread oxidative damage (Lulla et al., 2023). The brain is particularly vulnerable to oxidative stress because of its high oxygen consumption, abundant polyunsaturated fatty acids, high metabolic demand, and relatively limited antioxidant reserves. Excessive reactive species can induce lipid peroxidation, protein oxidation, DNA damage, mitochondrial membrane depolarization, and disruption of cellular energy metabolism. These events directly impair neuronal survival and also amplify other pathological processes, including neuroinflammation, blood brain barrier dysfunction, edema formation, and regulated cell death. In this context, oxidative stress is not merely a downstream consequence of trauma but a central driver that links multiple secondary injury cascades (Siddiqi et al., 2023). The redox imbalance after TBI provides a strong rationale for nanozyme therapy. Unlike conventional antioxidants that are consumed during redox reactions, nanozymes can catalytically convert harmful reactive species into less toxic products (Thomas, 2022). Nanozymes with superoxide dismutase like activity can promote the dismutation of superoxide anion, whereas those with catalase like or glutathione peroxidase like activity can further decompose hydrogen peroxide and organic peroxides. Some nanozymes also possess broad spectrum activity against both reactive oxygen species and reactive nitrogen species. Therefore, nanozymes are particularly attractive for TBI because they may provide sustained and catalytic regulation of the complex oxidative microenvironment within injured brain tissues (Tani et al., 2022). (Fig. 2).Fig. 2Pathological mechanisms of secondary brain injury after traumatic brain injury and potential therapeutic targets of nanozymes. Following mechanical trauma, oxidative stress, neuroinflammation, blood brain barrier dysfunction, lipid peroxidation, and neuronal injury interact to form a self-amplifying secondary injury cascade. By catalytically scavenging reactive oxygen and nitrogen species and regulating downstream pathological pathways, nanozymes attenuate oxidative damage, suppress neuroinflammation, preserve neurovascular integrity, inhibit ferroptosis, and facilitate neurological recovery.Fig. 2 Pathological mechanisms of secondary brain injury after traumatic brain injury and potential therapeutic targets of nanozymes. Following mechanical trauma, oxidative stress, neuroinflammation, blood brain barrier dysfunction, lipid peroxidation, and neuronal injury interact to form a self-amplifying secondary injury cascade. By catalytically scavenging reactive oxygen and nitrogen species and regulating downstream pathological pathways, nanozymes attenuate oxidative damage, suppress neuroinflammation, preserve neurovascular integrity, inhibit ferroptosis, and facilitate neurological recovery. The contribution of oxidative stress is not uniform across all TBI contexts. In mild TBI, oxidative injury may be spatially limited and closely linked to transient mitochondrial dysfunction, axonal injury, and neurovascular perturbation, whereas moderate to severe TBI is more often associated with hemorrhage, ischemia, edema, and sustained ROS/RNS generation. Injury mechanism is also important: focal contusion, diffuse axonal injury, blast injury, and TBI complicated by systemic hypotension can produce different redox patterns and therapeutic windows. Temporally, ROS/RNS production begins within minutes to hours after trauma, interacts with inflammation and blood brain barrier injury during the subacute phase, and may persist at lower levels during chronic neurodegenerative remodeling. Therefore, nanozyme therapy should be matched to injury severity, mechanism, and disease stage rather than viewed as a single uniform antioxidant strategy. Neuroinflammation and glial cell activation Neuroinflammation is another major component of secondary brain injury and is closely interconnected with oxidative stress (Turgeon et al., 2024). After TBI, damaged neurons, disrupted vessels, and necrotic tissue release danger associated molecular patterns that activate resident immune cells in the central nervous system. Microglia are rapidly activated and undergo phenotypic transformation. In the acute phase, excessive activation of proinflammatory microglia leads to the secretion of inflammatory mediators, including interleukin 1 beta, interleukin 6, tumor necrosis factor alpha, nitric oxide, and chemokines (Schiff et al., 2023; van Erp et al., 2023; Wang et al., 2025a). These mediators recruit peripheral immune cells, increase vascular permeability, and aggravate neuronal damage. Astrocytes also participate actively in the inflammatory response after TBI (Silvestro et al., 2024). Reactive astrocytes may initially contribute to tissue repair and metabolic support, but excessive or prolonged astrocyte activation can promote glial scar formation, disturb extracellular ion balance, and release inflammatory factors that worsen neuronal dysfunction. Importantly, microglia and astrocytes interact with each other during the progression of secondary injury. Proinflammatory microglia can induce neurotoxic astrocyte activation, whereas activated astrocytes can further sustain microglial inflammation (van Hameren et al., 2024). This bidirectional communication contributes to persistent inflammatory injury and may underlie chronic neurological deficits after TBI (Waltzman et al., 2022). Oxidative stress and neuroinflammation reinforce each other. Excessive reactive oxygen species can activate inflammatory signaling pathways such as nuclear factor kappa B and the NLRP3 inflammasome, thereby promoting cytokine release and glial activation. In turn, activated microglia and infiltrating immune cells generate additional reactive species through enzymes such as NADPH oxidase and inducible nitric oxide synthase (Prabhakar et al., 2022). This positive feedback loop between oxidative stress and inflammation accelerates neuronal loss and impairs functional recovery (Weng et al., 2025). Nanozymes can interrupt this pathological cycle by lowering reactive species levels, reducing inflammatory signaling, and shifting glial responses toward a less harmful state (Yang et al., 2024a). Therefore, anti-inflammatory effects are often considered a secondary but essential consequence of nanozyme mediated redox regulation (Yue et al., 2023). In addition to indirect anti-inflammatory effects caused by ROS reduction, several nanozyme systems appear to modulate inflammatory signaling more directly. Reported mechanisms include inhibition of NF kappa B activation, attenuation of NLRP3 inflammasome signaling, reduction of microglial M1 polarization, suppression of astrocyte reactivity, and activation of endogenous cytoprotective pathways such as Nrf2/HO 1. These effects may arise from catalytic regulation of redox sensitive signaling nodes, surface interactions with immune cells, or modulation of lipid peroxidation products that act as inflammatory mediators. Thus, nanozyme mediated immunomodulation should be evaluated not only by reduced cytokine levels but also by pathway specific markers and cell specific glial phenotypes. For TBI translation, nanozyme mediated immune modulation should be analyzed across both innate and adaptive immune components. Microglia can shift from acutely protective phagocytic states to sustained proinflammatory phenotypes, astrocytes can either support repair or amplify glial scarring, and infiltrating neutrophils, monocytes, and lymphocytes can reshape the lesion microenvironment. Nanozymes may influence these processes by reducing NADPH oxidase derived ROS, limiting mitochondrial danger signals, suppressing inflammasome activation, modulating nitric oxide and peroxynitrite production, and decreasing lipid peroxidation products that serve as inflammatory amplifiers. Future studies should therefore report microglial and astrocytic phenotypes, leukocyte infiltration, inflammasome activation, cytokine networks, and temporal changes in immune responses rather than describing inflammation only as a downstream consequence of ROS scavenging. Blood brain barrier disruption and cerebrovascular dysfunction The blood brain barrier is a specialized neurovascular interface formed by endothelial cells, tight junction proteins, pericytes, astrocytic end feet, and basement membrane components (Yan et al., 2025; Yue et al., 2024). It maintains brain homeostasis by regulating molecular transport, limiting immune cell infiltration, and protecting neural tissues from circulating toxins and inflammatory mediators (Amlerova et al., 2024). TBI frequently causes mechanical and biochemical damage to the cerebral microvasculature, leading to early disruption of blood brain barrier integrity (Rauchman et al., 2023; Yang et al., 2024b; Zhang et al., 2026) This disruption allows plasma proteins, immune cells, and inflammatory mediators to enter the brain parenchyma, thereby aggravating edema, neuroinflammation, and neuronal injury (Ghaith et al., 2022). Blood brain barrier damage is closely associated with oxidative stress. Reactive oxygen species can directly injure endothelial cells, degrade tight junction proteins, and activate matrix metalloproteinases that disrupt the extracellular matrix and vascular basement membrane (Freire et al., 2023; Hossain et al., 2024; Mielke et al., 2022). Peroxynitrite and other reactive nitrogen species can further damage endothelial mitochondria and impair vascular relaxation. As a result, TBI is often accompanied by increased vascular permeability, microvascular leakage, cerebral hypoperfusion, and impaired oxygen delivery. These vascular abnormalities further exacerbate mitochondrial dysfunction and reactive species production, creating another self-reinforcing injury loop. The pathological opening of the blood brain barrier presents both a challenge and an opportunity for nanozyme therapy. On one hand, intact regions of the barrier restrict the delivery of therapeutic agents to injured brain tissues. On the other hand, transient barrier disruption after trauma may facilitate the accumulation of appropriately designed nanomaterials at the lesion site. Nanozymes that reduce oxidative stress and inflammation may help restore vascular integrity by protecting endothelial cells, preserving tight junction proteins, and improving cerebral perfusion. In addition, imaging capable nanozymes provide an opportunity to monitor blood brain barrier status and guide treatment timing. Thus, the neurovascular unit is an important therapeutic target for nanozyme based intervention in TBI. Because BBB disruption after TBI is transient and regionally heterogeneous, efficient delivery across relatively intact barrier regions remains a major design requirement. Current strategies include reducing particle size, optimizing surface charge and hydrophilicity, PEGylation or zwitterionic modification to prolong circulation, receptor mediated transport using transferrin, insulin, low density lipoprotein receptor, or cell adhesion molecule targeting ligands, and biomimetic approaches such as cell membrane or exosome inspired coatings. Focused ultrasound, intranasal delivery, injectable hydrogels, and local peri-lesional administration may also be considered for subacute or chronic stages when passive leakage is limited. These approaches need quantitative pharmacokinetic and brain distribution analyses rather than relying solely on post-injury BBB opening. Lipid peroxidation, ferroptosis, and regulated cell death Lipid peroxidation is a critical downstream consequence of oxidative stress and plays a central role in neuronal injury after TBI (Bolte et al., 2023). The brain contains high levels of polyunsaturated fatty acids, which are highly susceptible to oxidative attack (Fesharaki-Zadeh, 2022). Excessive reactive species initiate lipid peroxidation chain reactions that generate toxic products such as malondialdehyde, 4 hydroxynonenal, and lipid hydroperoxides (Bonanno et al., 2022). These products damage cellular membranes, impair mitochondrial function, alter ion homeostasis, and propagate oxidative injury to neighboring cells. As lipid peroxidation accumulates, membrane integrity becomes compromised, which contributes to neuronal dysfunction and cell death. Ferroptosis has recently attracted increasing attention as a form of regulated cell death associated with iron accumulation, glutathione depletion, glutathione peroxidase 4 inactivation, and excessive lipid peroxidation (Cherian et al., 2024). Although apoptosis and necrosis have long been recognized in TBI pathology, ferroptosis provides a mechanistic framework that connects redox imbalance, iron metabolism, mitochondrial dysfunction, and membrane lipid damage (Gaudette et al., 2022). In the injured brain, iron release from damaged cells and hemorrhagic components may further promote Fenton chemistry and hydroxyl radical generation (Luo et al., 2024). This process amplifies lipid peroxidation and contributes to progressive neuronal loss. Emerging evidence also suggests that enzymatic lipid oxidation pathways are involved in brain injury. Arachidonate lipoxygenases, including ALOX12, can promote lipid peroxide formation and inflammatory signaling. Inhibition of ALOX12 related lipid peroxidation has been associated with reduced reactive species accumulation, decreased proinflammatory microglial activation, and improved neuronal survival in experimental brain injury models. This finding expands the therapeutic role of nanozymes beyond passive scavenging of reactive species. Properly designed nanozymes may regulate disease relevant molecular pathways, suppress lipid peroxidation, and modulate inflammatory cell death programs. Therefore, lipid peroxidation and ferroptosis represent important pathological targets for next generation nanozyme therapy in TBI. (Table 1).Table 1Pathological mechanisms of secondary injury after TBI and potential nanozyme intervention targets.Pathological eventMajor mediatorsBiological consequencesPotential nanozyme interventionOxidative stressO₂•−, H₂O₂, •OH, ONOO−Lipid peroxidation, mitochondrial dysfunctionSOD-like, CAT-like, GPx-like activityNeuroinflammationMicroglia, astrocytes, TNF-α, IL-1βNeuronal damage, cytokine stormROS suppression, inflammatory pathway modulationBBB disruptionMMPs, ROS, endothelial injuryEdema, immune infiltrationEndothelial protection, vascular repairFerroptosisFe2+, lipid peroxides, ALOX12Neuronal deathLipid peroxide eliminationMitochondrial dysfunctionROS accumulation, ATP depletionEnergy failureRedox regulation Table 1Pathological mechanisms of secondary injury after TBI and potential nanozyme intervention targets.Pathological eventMajor mediatorsBiological consequencesPotential nanozyme interventionOxidative stressO₂•−, H₂O₂, •OH, ONOO−Lipid peroxidation, mitochondrial dysfunctionSOD-like, CAT-like, GPx-like activityNeuroinflammationMicroglia, astrocytes, TNF-α, IL-1βNeuronal damage, cytokine stormROS suppression, inflammatory pathway modulationBBB disruptionMMPs, ROS, endothelial injuryEdema, immune infiltrationEndothelial protection, vascular repairFerroptosisFe2+, lipid peroxides, ALOX12Neuronal deathLipid peroxide eliminationMitochondrial dysfunctionROS accumulation, ATP depletionEnergy failureRedox regulation Pathological mechanisms of secondary injury after TBI and potential nanozyme intervention targets. Ferroptosis should also be considered together with other regulated cell death pathways after TBI. Apoptosis is characterized by caspase activation and mitochondrial or death receptor signaling and is well suited to targeted molecular inhibitors, but single pathway blockade may be insufficient. Necroptosis involves RIPK1/RIPK3/MLKL signaling and contributes to inflammatory membrane rupture, while pyroptosis is driven by inflammasome activation, gasdermin pore formation, and cytokine release. Ferroptosis is particularly relevant to nanozyme therapy because it is directly linked to iron dependent lipid peroxidation, GPX4 dysfunction, glutathione depletion, and ROS amplification. Nanozymes may therefore be especially suitable for ferroptosis associated secondary injury, while their broader redox and anti-inflammatory functions may also influence apoptosis, necroptosis, and pyroptosis indirectly. Nanozyme strategies against ferroptosis extend beyond simple suppression of Fenton chemistry. GPx like nanozymes can decompose lipid hydroperoxides and partially compensate for impaired GPX4 activity; catalase like or SOD like nanozymes can reduce upstream ROS that initiate lipid radical formation; cerium, manganese, selenium, tellurium, and single atom or metal nitrogen carbon systems may be engineered to regulate lipid ROS without increasing free iron burden; and pathway oriented platforms such as KNC suggest that nanozymes may interfere with ALOX12 mediated enzymatic lipid oxidation. Future TBI studies should measure ferroptosis specific endpoints, including GPX4, ACSL4, SLC7A11, FSP1, ferritinophagy, labile iron, 4 hydroxynonenal, malondialdehyde, and mitochondrial morphological changes, to distinguish true anti-ferroptotic effects from nonspecific antioxidant activity. Conventional therapeutic strategies and their limitations Current clinical management of TBI mainly focuses on preventing secondary insults, stabilizing systemic physiology, and controlling intracranial complications. In the acute phase, treatment strategies include airway protection, maintenance of oxygenation and cerebral perfusion, control of intracranial pressure, surgical evacuation of mass lesions, decompressive craniectomy in selected patients, seizure prophylaxis, and intensive neurocritical care. These interventions are essential for reducing mortality and preventing further neurological deterioration. However, most of them are supportive or symptomatic rather than disease modifying (Mu et al., 2024). They do not directly reverse the molecular cascades that drive progressive secondary brain injury, including oxidative stress, neuroinflammation, mitochondrial dysfunction, blood brain barrier disruption, lipid peroxidation, and regulated neuronal death (Bielefeld et al., 2024). Several pharmacological strategies have been investigated for neuroprotection after TBI, including corticosteroids, excitotoxicity inhibitors, calcium channel modulators, free radical scavengers, anti-inflammatory agents, mitochondrial protective compounds, and agents targeting apoptosis or edema formation. However, many candidates that showed promise in preclinical studies failed to demonstrate clear benefits in clinical trials. This translational gap is partly attributable to the complexity and heterogeneity of TBI. Patients differ markedly in injury mechanism, lesion location, severity, age, comorbidities, therapeutic time window, and systemic complications (Zhang et al., 2024b). A single molecular target is therefore unlikely to fully control the broad and dynamic pathological network of secondary injury. Antioxidant therapy is particularly relevant to the rationale of nanozyme development. Because oxidative stress is a central driver of secondary injury, numerous natural enzymes and small molecule antioxidants have been explored (Armstrong et al., 2024). Nevertheless, conventional antioxidants face several intrinsic limitations. Natural antioxidant enzymes such as superoxide dismutase and catalase are susceptible to degradation, have short circulation times, may induce immune responses, and generally show poor penetration into injured brain tissues. Small molecule antioxidants are often rapidly consumed during redox reactions and may lack sufficient catalytic capacity to counteract persistent ROS and RNS production (Zhao et al., 2023). In addition, many antioxidants show poor accumulation at the lesion site and limited ability to simultaneously regulate multiple reactive species, inflammatory pathways, and vascular injury. Clinical experience with antioxidant and neuroprotective agents illustrates why translation has been difficult. Free radical scavengers and lipid peroxidation inhibitors may be effective in simplified experimental systems, but their clinical performance is limited by short therapeutic windows, rapid consumption, inadequate brain exposure, dose limiting systemic toxicity, and inability to address the heterogeneity of human TBI. Agents such as corticosteroids, progesterone, magnesium, and other broadly neuroprotective or antioxidant associated therapies have failed to show consistent benefit in large clinical studies, partly because they target only selected components of a dynamic injury network. In addition, many trials enrolled heterogeneous patients without biomarker guided selection, did not align dosing with the temporal evolution of oxidative stress, and used outcomes that may not capture pathway specific biological effects. These failures suggest that next generation catalytic therapies should combine durable activity, lesion targeted delivery, mechanistic biomarkers, and clinically realistic dosing windows. Another major limitation of conventional pharmacological treatment is the blood brain barrier. Although TBI can transiently disrupt blood brain barrier integrity, this disruption is spatially and temporally heterogeneous (Zhong et al., 2025). Many drugs still fail to reach effective concentrations within the injured brain, especially in regions where the barrier remains partially intact or rapidly recovers. Systemic administration may also increase peripheral side effects before sufficient drug levels are achieved in the central nervous system (Liao et al., 2023; Shi et al., 2025a; Zang et al., 2025; Liao et al., 2026a). Therefore, therapeutic platforms capable of improving brain delivery, lesion accumulation, and local retention are urgently needed. The dynamic nature of TBI further complicates treatment. Oxidative stress, inflammation, vascular dysfunction, edema, cell death, and tissue remodeling do not occur simultaneously or with equal intensity. Instead, they evolve across acute, subacute, and chronic stages. Conventional therapies often target only one aspect of this cascade and may not adapt to the changing pathological microenvironment. For example, reducing excitotoxicity alone may be insufficient if mitochondrial dysfunction and lipid peroxidation continue to drive neuronal death. Similarly, anti-inflammatory treatment may be ineffective or even harmful if administered at an inappropriate stage, because inflammation may contribute to both injury progression and tissue repair (Oris et al., 2023). These limitations highlight the need for therapeutic strategies that are multifunctional, catalytic, and adaptable to the injured brain microenvironment (Wang et al., 2025b; Wang et al., 2025c; Xie et al., 2025; Zhu et al., 2025a; Feng et al., 2026). Nanozymes are well positioned to address some of these unmet needs. By mimicking natural antioxidant enzymes, nanozymes can catalytically remove excessive ROS and RNS rather than being consumed in a single reaction (Fu et al., 2025; Li et al., 2024; Zheng et al., 2024b). Through rational design of composition, size, surface chemistry, and targeting ligands, nanozymes may achieve improved lesion accumulation and prolonged activity (Newcombe et al., 2022). Moreover, some nanozymes can integrate multiple functions, including antioxidant catalysis, anti-inflammatory regulation, blood brain barrier protection, imaging guidance, and modulation of lipid peroxidation related pathways (Liao et al., 2022; Huang et al., 2025; Li et al., 2026; Wu et al., 2026a). Therefore, nanozyme based therapeutic strategies provide a promising direction for overcoming the limitations of conventional TBI treatments and will be discussed in detail in the following section. (Table 2).Table 2Conventional therapeutic strategies for TBI and their major limitations.Therapeutic strategyRepresentative approachesPrimary mechanismCurrent limitationsPotential advantages of nanozymesSurgical interventionHematoma evacuation, decompressive craniectomyRelieves intracranial pressure and mass effectDoes not directly prevent secondary injuryNanozymes can target secondary injury cascades after surgeryNeurocritical careOxygen therapy, blood pressure management, ICP monitoringMaintains cerebral perfusion and systemic stabilityPrimarily supportive rather than neuroprotectiveNanozymes may provide direct neuroprotectionAnti edema therapyMannitol, hypertonic salineReduces cerebral edema and intracranial pressureTemporary effect, limited influence on molecular pathologyNanozymes may reduce edema by attenuating oxidative and vascular injuryAnti-inflammatory therapyCorticosteroids, NSAIDs, cytokine inhibitorsSuppresses inflammatory responsesLimited efficacy and potential systemic side effectsNanozymes can simultaneously regulate oxidative stress and inflammationAntioxidant therapyEdaravone, N-acetylcysteine, vitamin ENeutralizes reactive oxygen speciesRapid consumption, poor catalytic capacity, limited brain accumulationNanozymes provide catalytic and sustained ROS eliminationExcitotoxicity inhibitionNMDA receptor antagonistsReduces glutamate mediated neuronal injuryNarrow therapeutic window and adverse effectsNanozymes indirectly attenuate excitotoxic damage through redox regulationCalcium channel modulationNimodipine and related agentsReduces calcium overloadInconsistent clinical benefitNanozymes may complement calcium regulation by protecting mitochondriaAnti apoptotic therapyCaspase inhibitors, mitochondrial protectantsInhibits programmed cell deathSingle pathway targetingNanozymes can regulate multiple interconnected pathwaysFerroptosis inhibitionFerrostatin-1, liproxstatin-1Prevents lipid peroxidation and iron dependent cell deathMostly preclinical evidenceCertain nanozymes can suppress lipid peroxidation while scavenging ROSStem cell therapyMSCs, neural stem cellsTissue repair and immunomodulationLow survival, poor engraftment, manufacturing complexityNanozymes may improve the injury microenvironment and support regenerative therapies Table 2Conventional therapeutic strategies for TBI and their major limitations.Therapeutic strategyRepresentative approachesPrimary mechanismCurrent limitationsPotential advantages of nanozymesSurgical interventionHematoma evacuation, decompressive craniectomyRelieves intracranial pressure and mass effectDoes not directly prevent secondary injuryNanozymes can target secondary injury cascades after surgeryNeurocritical careOxygen therapy, blood pressure management, ICP monitoringMaintains cerebral perfusion and systemic stabilityPrimarily supportive rather than neuroprotectiveNanozymes may provide direct neuroprotectionAnti edema therapyMannitol, hypertonic salineReduces cerebral edema and intracranial pressureTemporary effect, limited influence on molecular pathologyNanozymes may reduce edema by attenuating oxidative and vascular injuryAnti-inflammatory therapyCorticosteroids, NSAIDs, cytokine inhibitorsSuppresses inflammatory responsesLimited efficacy and potential systemic side effectsNanozymes can simultaneously regulate oxidative stress and inflammationAntioxidant therapyEdaravone, N-acetylcysteine, vitamin ENeutralizes reactive oxygen speciesRapid consumption, poor catalytic capacity, limited brain accumulationNanozymes provide catalytic and sustained ROS eliminationExcitotoxicity inhibitionNMDA receptor antagonistsReduces glutamate mediated neuronal injuryNarrow therapeutic window and adverse effectsNanozymes indirectly attenuate excitotoxic damage through redox regulationCalcium channel modulationNimodipine and related agentsReduces calcium overloadInconsistent clinical benefitNanozymes may complement calcium regulation by protecting mitochondriaAnti apoptotic therapyCaspase inhibitors, mitochondrial protectantsInhibits programmed cell deathSingle pathway targetingNanozymes can regulate multiple interconnected pathwaysFerroptosis inhibitionFerrostatin-1, liproxstatin-1Prevents lipid peroxidation and iron dependent cell deathMostly preclinical evidenceCertain nanozymes can suppress lipid peroxidation while scavenging ROSStem cell therapyMSCs, neural stem cellsTissue repair and immunomodulationLow survival, poor engraftment, manufacturing complexityNanozymes may improve the injury microenvironment and support regenerative therapies Conventional therapeutic strategies for TBI and their major limitations. Nanozyme therapeutic strategies for TBI Nanozymes are nanomaterials that possess intrinsic enzyme mimicking catalytic activities. Since the discovery that certain inorganic nanoparticles can catalyze enzyme like reactions, nanozymes have rapidly evolved from analytical tools for biosensing into a broad class of catalytic nanomedicines (Panferov et al., 2024; Yuan et al., 2024; Ma et al., 2025). Early studies mainly focused on peroxidase like activity, particularly for colorimetric detection and diagnostic applications. With advances in nanomaterial synthesis, surface engineering, and catalytic mechanism analysis, the concept of nanozymes has expanded to include materials with superoxide dismutase like, catalase like, glutathione peroxidase like, oxidase like, and multi enzyme mimicking activities (Ma et al., 2024; Xu et al., 2024a; Zeng et al., 2023). This evolution has enabled nanozymes to be applied not only in detection systems but also in disease treatment, especially in pathological conditions associated with oxidative stress and inflammation (Perumal et al., 2023; Yixin et al., 2025; Wang et al., 2023). The development of nanozymes is closely related to the limitations of natural enzymes (Liao et al., 2025a). Endogenous antioxidant enzymes such as superoxide dismutase, catalase, and glutathione peroxidase are essential for maintaining redox homeostasis. However, the direct therapeutic use of natural enzymes is limited by poor stability, high production cost, short circulation time, potential immunogenicity, and difficulty in crossing biological barriers (Cong et al., 2024; Shang et al., 2023; Li et al., 2023b). Conventional small molecule antioxidants also face major challenges, including rapid consumption during redox reactions, limited catalytic capacity, poor lesion accumulation, and insufficient efficacy in complex disease microenvironments. Nanozymes provide an alternative strategy because they combine the catalytic features of enzymes with the physicochemical advantages of nanomaterials (Sen et al., 2024; Wang et al., 2024a; Sommonte et al., 2024). (Fig. 3).Fig. 3Timeline of the development of nanozyme research, highlighting the transition from the discovery of enzyme-mimetic activity in nanomaterials to multifunctional catalytic platforms, immune-related applications, and current translational challenges including precision control, biosafety, and scalable manufacturing.Fig. 3 Timeline of the development of nanozyme research, highlighting the transition from the discovery of enzyme-mimetic activity in nanomaterials to multifunctional catalytic platforms, immune-related applications, and current translational challenges including precision control, biosafety, and scalable manufacturing. Compared with natural enzymes and conventional antioxidants, nanozymes offer several advantages for TBI therapy (Meng et al., 2024; Mouli et al., 2025; Singh et al., 2025; Tao et al., 2025; Yu et al., 2025). First, nanozymes can catalytically and repeatedly remove excessive reactive oxygen species and reactive nitrogen species rather than being consumed in a single redox reaction. This property is particularly important for TBI, where oxidative stress is not a transient event but a sustained process during secondary brain injury (Peng et al., 2024; Zhang et al., 2024c; Guo et al., 2025; Hong et al., 2025). Second, the catalytic activity of nanozymes can be adjusted by controlling composition, particle size, morphology, surface functional groups, valence state, dopant distribution, and electronic structure. For example, carbon based nanozymes can be optimized by regulating conjugated carbon domains and oxygen containing functional groups, whereas metal based nanozymes can be tuned by alloying, doping, or exposing specific active sites (Shamsabadi et al., 2024; Wang et al., 2024b; Bo et al., 2024; Xiyu et al., 2025). Third, nanozymes can be integrated with other functions, including targeted delivery, imaging, drug loading, and responsiveness to pathological microenvironments. These features allow nanozymes to act as multifunctional therapeutic platforms rather than simple antioxidant agents. TBI represents a suitable disease context for nanozyme intervention because its secondary injury cascade is strongly driven by redox imbalance. After mechanical trauma, excessive production of superoxide anion, hydrogen peroxide, hydroxyl radicals, nitric oxide, and peroxynitrite contributes to mitochondrial dysfunction, lipid peroxidation, neuroinflammation, blood brain barrier disruption, and neuronal death (Song et al., 2024; Xu et al., 2024b; Han et al., 2025; Jia et al., 2025). Nanozymes with superoxide dismutase like activity can catalyze the conversion of superoxide anion, while nanozymes with catalase like or glutathione peroxidase like activity can further decompose hydrogen peroxide and lipid peroxides (Wang et al., 2024c; Yang et al., 2024c; Jiang et al., 2025; Shi et al., 2025b). Some nanozymes can also scavenge reactive nitrogen species and reduce peroxynitrite associated damage. Therefore, nanozymes are well matched to the complex oxidative microenvironment of injured brain tissue (Luyan et al., 2024; Khramtsov et al., 2025; Wang et al., 2025d). Another important advantage of nanozymes lies in their design flexibility. Different categories of nanozymes can be selected according to specific therapeutic needs (Wu et al., 2024; Sun et al., 2025; Yang et al., 2024). Carbon based nanozymes usually show favorable biocompatibility, tunable electronic structures, and potential clearance advantages (Lu et al., 2024; Daksh et al., 2025; Wu et al., 2026b). Metal based nanozymes often exhibit high catalytic efficiency and broad reactive species scavenging capacity (Zhuang et al., 2024; Zhou et al., 2025; Yu et al., 2026). Semiconductor nanozymes can integrate catalytic therapy with optical imaging, allowing real time monitoring of blood brain barrier dysfunction and cerebral perfusion. Metal nitrogen carbon nanozymes provide well defined catalytic centers and may regulate disease related molecular pathways beyond direct ROS scavenging (Xiao et al., 2023; Xie et al., 2024; Li et al., 2025a; Pan et al., 2025). This diversity makes it possible to design nanozyme platforms for different stages and pathological features of TBI. Importantly, the field is moving from empirical antioxidant nanomaterials toward rationally designed catalytic nanomedicines (McHugh et al., 2024; Tian et al., 2025; Xiang et al., 2026). Early nanozyme studies mainly asked whether a material could reduce ROS and improve cell survival. More recent studies have begun to investigate how structure determines catalytic activity, how electron transfer controls reaction kinetics, how nanozymes interact with biological pathways, and how catalytic therapy can be combined with imaging or targeted delivery (Lin et al., 2024; Hwang et al., 2025; Li et al., 2025b). For example, oligomeric carbon nanozymes have been engineered to achieve ultrafast electron transfer and strong antioxidant activity in acute brain injury (Zhu et al., 2025b; Liao et al., 2026b; Liao et al., 2026c; Liao et al., 2026d). Oxidized activated charcoal nanozymes have been studied through a process structure property performance framework, supporting translational optimization. NIR IIb fluorescent nanozymes have demonstrated the feasibility of imaging guided treatment by dynamically monitoring blood brain barrier status. Metal nitrogen carbon nanozymes have further suggested that nanozymes may regulate lipid peroxidation related pathways such as ALOX12 rather than only scavenging ROS. Despite these advantages, nanozyme therapy for TBI is still at a preclinical stage. Several challenges remain, including efficient delivery across the blood brain barrier, long term biosafety, catalytic selectivity under physiological conditions, standardized activity evaluation, and reproducible large-scale manufacturing (Jana et al., 2024; Liu et al., 2024a; Liu et al., 2024b). In addition, the biological effects of nanozymes should be understood in the context of redox homeostasis rather than simple ROS elimination. Reactive species are harmful when excessive, but they also participate in physiological signaling, vascular regulation, immune defense, and tissue repair. Therefore, future nanozymes should be designed to restore redox balance and regulate disease specific pathways rather than indiscriminately eliminate all reactive species (Fan et al., 2024; Jiang et al., 2024; Liu et al., 2024c). Based on their composition, structure, and functional characteristics, nanozymes explored for TBI and related brain injuries can be broadly divided into carbon based nanozymes, metal based nanozymes, semiconductor nanozymes, and metal nitrogen carbon nanozymes. The following sections summarize the basic features of each category and discuss representative studies, with emphasis on catalytic mechanisms, therapeutic outcomes, and translational potential. This classification is intended as a practical framework rather than a rigid taxonomy. Carbon based, metal based, semiconductor, and metal nitrogen carbon nanozymes differ in dominant catalytic centers, electronic structures, degradation behavior, imaging potential, and translational risks, which makes the categories useful for comparing design principles. Hybrid or multifunctional nanozymes can be placed according to the component that provides the primary catalytic activity, while their auxiliary functions, such as targeting, imaging, drug loading, or biomimetic coating, should be described separately. For example, a carbon nanozyme decorated with a targeting ligand remains primarily carbon based, whereas a semiconductor quantum dot with catalytic metal doping is best discussed as a semiconductor nanozyme with dopant mediated activity. This flexible classification helps compare materials without obscuring multifunctional design. Carbon based nanozymes Carbon based nanozymes represent an important class of catalytic nanomaterials for the treatment of oxidative stress related neurological injury. Their antioxidant activity is generally associated with conjugated carbon domains, defect sites, heteroatom doping, and oxygen containing functional groups (Han et al., 2024). These structural features can facilitate electron transfer and enable the catalytic elimination of reactive oxygen species and reactive nitrogen species. Compared with many inorganic nanozymes, carbon based nanozymes usually show favorable biocompatibility, relatively low metal related toxicity, flexible surface chemistry, and potential for renal or hepatic clearance depending on their size and surface properties (Han et al., 2022). In the context of TBI, carbon based nanozymes are attractive because oxidative stress emerges rapidly after trauma and persists during the secondary injury phase. Therefore, catalytic materials with sustained redox regulatory ability may provide advantages over conventional antioxidants that are rapidly consumed. A representative example is the oligomeric nanozyme O-NZ reported by Mu and colleagues (Mu et al., 2021). O-NZ was designed with a nitrogen doped graphite like core and surface-active groups, including amide groups, hydroxyl groups, and pyrrolic nitrogen. This structure allowed efficient interaction with multiple reactive species. The material showed an average core diameter of approximately 2.8 nm and a hydrodynamic size of approximately 3.4 nm, which is below the commonly accepted renal filtration threshold. Mechanistically, O-NZ exhibited ultrafast electron transfer within the internal core in approximately 1.8 ns and electron transfer between the core and surface ligand groups in approximately 1.2 ps. These electron transfer characteristics were proposed to be responsible for its high catalytic activity and rapid radical scavenging capacity. In catalytic assays, O-NZ showed strong superoxide dismutase like and glutathione peroxidase like activities. For glutathione peroxidase like activity, the maximum reaction rates for hydrogen peroxide and glutathione were 72.97 and 18.49 μM min − 1, respectively. The Michaelis constants for hydrogen peroxide and glutathione were 0.8204 and 0.8688 mM, respectively, indicating a relatively high substrate affinity compared with natural glutathione peroxidase for glutathione. In a severe TBI mouse model, O-NZ produced pronounced neuroprotective effects. T2 weighted magnetic resonance imaging showed that untreated TBI mice developed progressive edema and secondary lesions, whereas O-NZ treatment markedly limited the spread of secondary injury. More importantly, the 30-day survival rate increased from 50% in untreated TBI mice to 90% in O-NZ treated mice, whereas edaravone treatment only increased survival to 60%. O-NZ also improved blood brain barrier integrity, reduced apoptotic signals in the injured cortex, and improved long term behavioral outcomes, including spatial learning, memory performance, motor coordination, and neurological severity scores. At the molecular level, O-NZ reduced nitric oxide, hydrogen peroxide, oxidized glutathione, and lipid peroxide levels and restored inflammatory factors such as TNF alpha and IL 1 beta toward normal levels. The study further suggested that O-NZ may exert its neuroprotective function partly through activation of the Nrf2 and HO 1 pathway. This work is important because it shifts the design principle of carbon nanozymes from simple radical scavenging to catalytic electron transfer engineering. The ultrafast electron transfer feature provides a mechanistic explanation for why O-NZ can simultaneously regulate multiple reactive species in the injured brain. In addition, the small size, short blood half-life of approximately 26.3 min, and nearly 80% renal clearance within 12 h support its potential biosafety advantage over many inorganic nanozymes. However, the short circulation time may also limit sustained exposure in the injured brain, and the balance between rapid clearance and sufficient therapeutic residence remains an important issue for future optimization. (Fig. 4).Fig. 4Structural features and in vivo efficacy of O-NZ. (A–C) Illustration of O-NZ showing a nitrogen-doped graphite-like core that provides multi-enzyme activity and surface functional groups serving as hydrogen donors. (E) Representative T2-weighted MRI images of mice in the TBI, TBI + edaravone, and TBI + O-NZ groups at 5, 17, and 30 days post-injury. Hyperintense regions surrounding the primary lesion (red arrows) indicate secondary damage. Images include slices 1 mm anterior and posterior to the impact site. (F) Quantitative analysis of the hyperintense lesion volumes across all MRI slices. (G) Survival curves of TBI mice treated with O-NZ over 30 days, with edaravone as a positive control. (H) Representative brain images at 1 and 3 days post-injury following intravenous Evans Blue injection. (I) Quantification of blood–brain barrier permeability based on Evans Blue staining in O-NZ–treated and untreated TBI mice (n = 3). Copyright from (Mu et al., 2021). AAAS 2021. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 4 Structural features and in vivo efficacy of O-NZ. (A–C) Illustration of O-NZ showing a nitrogen-doped graphite-like core that provides multi-enzyme activity and surface functional groups serving as hydrogen donors. (E) Representative T2-weighted MRI images of mice in the TBI, TBI + edaravone, and TBI + O-NZ groups at 5, 17, and 30 days post-injury. Hyperintense regions surrounding the primary lesion (red arrows) indicate secondary damage. Images include slices 1 mm anterior and posterior to the impact site. (F) Quantitative analysis of the hyperintense lesion volumes across all MRI slices. (G) Survival curves of TBI mice treated with O-NZ over 30 days, with edaravone as a positive control. (H) Representative brain images at 1 and 3 days post-injury following intravenous Evans Blue injection. (I) Quantification of blood–brain barrier permeability based on Evans Blue staining in O-NZ–treated and untreated TBI mice (n = 3). Copyright from (Mu et al., 2021). AAAS 2021. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) At present, the remarkable efficacy of O-NZ has mainly been demonstrated in the original small animal TBI studies, and independent replication by other research groups remains limited. Large animal validation has not yet been reported for this platform. Before clinical translation, O-NZ and related ultrasmall carbon nanozymes should be tested in additional injury models, both sexes, aged animals, delayed dosing paradigms, and preferably large animal models that better reproduce human brain size, vascular anatomy, pharmacokinetics, and neurocritical care conditions. Another important carbon-based example is the oxidized activated charcoal nanozyme developed by McHugh and colleagues (McHugh et al., 2024). This study focused on coconut derived oxidized activated charcoal as a superoxide dismutase mimetic nanozyme. Compared with many carbon nanomaterials derived from carbon nanotubes or coal, coconut shell activated charcoal is particularly interesting because activated charcoal is already familiar to the medical community and can be obtained from a good manufacturing practice grade source. The authors systematically studied how oxidation conditions affected particle size, elemental composition, electrochemical properties, and biological antioxidant activity. Longer oxidation durations generated smaller and more homogeneous nanoparticles. The optimized sieved cOAC particles showed an average carbon core diameter of approximately 3.2 nm, whereas bulk cOAC particles showed an average diameter of approximately 4.2 nm. After PEGylation, PEG cOAC nanoparticles protected bEnd.3 brain endothelial cells from hydrogen peroxide induced injury. In the cell study, PEG cOAC at 4 mg L − 1 was not inherently toxic, and treatment after exposure to 100 μM hydrogen peroxide significantly improved cell viability. In a clinically relevant rat model combining mild TBI with hemorrhagic hypotension and resuscitation, PEG cOAC was administered intravenously at 2 mg kg − 1 at 80 min after injury. Brain perfusion was used as the primary outcome. At 120 min, regional cerebral perfusion in the central injured region remained markedly higher in the PEG cOAC group than in the PBS group, with values of 83.5 ± 1.5% and 39.8 ± 2.6%, respectively. In the penumbra, PEG cOAC also improved perfusion to 80.2 ± 1.2%, compared with 45.7 ± 2.2% in the PBS group. Notably, the effect of a single PEG cOAC dose was comparable to that of PEG HCCs, which required two doses in the experimental design. (Fig. 5).Fig. 5(A) Schematic representation of the oxidation-assisted fabrication of cOAC and subsequent PEGylation to obtain PEG-cOAC nanozymes. (B) Illustration of the experimental TBI model showing the impact-induced lesion core and the surrounding penumbral region, where cerebral blood flow was quantified by laser Doppler speckle imaging. (C) Longitudinal analysis of regional perfusion in the lesion core and penumbra following administration of PEG-cOAC, PEG-HCC, or PBS, demonstrating the effects of nanozyme treatment on post-traumatic cerebrovascular recovery. Copyright from (McHugh et al., 2024). Wiley-VCH 2022.Fig. 5 (A) Schematic representation of the oxidation-assisted fabrication of cOAC and subsequent PEGylation to obtain PEG-cOAC nanozymes. (B) Illustration of the experimental TBI model showing the impact-induced lesion core and the surrounding penumbral region, where cerebral blood flow was quantified by laser Doppler speckle imaging. (C) Longitudinal analysis of regional perfusion in the lesion core and penumbra following administration of PEG-cOAC, PEG-HCC, or PBS, demonstrating the effects of nanozyme treatment on post-traumatic cerebrovascular recovery. Copyright from (McHugh et al., 2024). Wiley-VCH 2022. The major contribution of the cOAC study lies in its translational orientation. Rather than only demonstrating therapeutic efficacy, this work established a relationship between synthesis, structure, physicochemical properties, and biological performance. The finding that particle size distribution and carbonyl to carboxylic acid ratio influence antioxidant protection provides a rational basis for optimizing carbon nanozymes. Moreover, the use of a medically familiar starting material and scalable synthesis considerations makes cOAC a valuable platform for future clinical translation. Nevertheless, the therapeutic readout in this study was mainly focused on acute cerebrovascular perfusion rather than long term neurobehavioral recovery. Future studies should further evaluate its effects on neuroinflammation, neuronal survival, cognitive outcomes, biodistribution, degradation, and repeated dose safety. For cOAC and other carbon based nanozymes, scalability does not automatically guarantee regulatory readiness. Large scale production must control raw material variability, oxidation strength, particle size distribution, oxygen containing functional groups, PEG conjugation efficiency, endotoxin burden, residual reagents, aggregate formation, and storage stability. Because catalytic activity depends sensitively on surface chemistry and electronic structure, release testing should include both physicochemical attributes and functional enzyme like assays. Batch to batch consistency, sterile formulation, environmental safety of oxidative processing, and compatibility with good manufacturing practice will be decisive for whether this translationally attractive platform can progress beyond proof of concept studies. Metal based nanozymes Metal based nanozymes are among the most extensively studied artificial enzymes because transition metals and noble metals can participate in electron transfer reactions and redox cycling (Kang et al., 2022; Zhang et al., 2023a). Representative metal nanozymes include cerium oxide, manganese oxide, iron oxide, platinum, palladium, and their alloyed or doped derivatives (Yao et al., 2022). These materials can exhibit superoxide dismutase like, catalase like, peroxidase like, oxidase like, and other enzyme mimicking activities depending on their composition, valence state, exposed crystal facets, and local coordination environment (Shen et al., 2023). In neurological injury, metal based nanozymes are particularly useful because they can catalytically remove multiple reactive species and modulate the oxidative microenvironment. However, their therapeutic application also requires careful consideration of catalytic selectivity, metal retention, long term safety, and activity under physiological conditions. A representative metal based nanozyme relevant to brain injury is the trimetallic PtPdMo nanozyme reported by Mu and colleagues (Xiaoyu et al., 2019). This triM nanozyme was designed to improve both catalytic activity and environmental selectivity. The introduction of molybdenum into a PtPd system induced lattice distortion and exposed more active sites, thereby enhancing catalytic performance. The material showed multi enzyme mimicking activity and could remove several reactive oxygen and nitrogen species, including singlet oxygen, hydrogen peroxide, hydroxyl radicals, and nitric oxide. A key feature of this system was its preference for a neutral environment. Since the physiological pH of the brain is close to 7.4, this property is important because many classical nanozymes show optimal activity under acidic conditions, which limits their efficacy in normal physiological environments. In a lipopolysaccharide induced brain injury model, triM nanozyme treatment improved survival and reduced neuroinflammatory injury. In the survival study, the survival rate of mice exposed to lipopolysaccharide alone decreased rapidly to 10% within 2 days. Treatment with triM nanozymes increased survival to 40% over 14 days, whereas aspirin increased survival to 20%. Brain uptake of triM nanozymes increased after lipopolysaccharide stimulation, which was attributed to transient blood brain barrier disruption. Biochemical analyses showed that triM nanozyme treatment rescued lipid peroxidation and improved superoxide dismutase activity in the brain. Immunofluorescence staining further demonstrated reduced GFAP positive astrocyte activation and Iba1 positive microglial activation in the hippocampus. In the Morris water maze test, triM treatment improved reference memory and spatial cognition compared with untreated injured mice. Toxicological evaluation showed no apparent pathological damage in major organs over 30 days, and hematological and biochemical markers such as white blood cells, red blood cells, alanine aminotransferase, aspartate aminotransferase, and creatinine showed no meaningful differences compared with controls. The triM study highlights the importance of catalytic selectivity in brain injury treatment. Because different reactive species have distinct biological functions, indiscriminate elimination may not always be beneficial. For example, nitric oxide can be harmful at excessive levels but also serves as a signaling molecule involved in vascular regulation. Therefore, a nanozyme that works efficiently in the physiological environment and regulates multiple reactive species in a controlled manner may be more suitable for central nervous system diseases than a material that only shows strong activity in artificial acidic assays. However, this study used a lipopolysaccharide induced brain injury model rather than a mechanical TBI model. Thus, although the results are highly relevant to neuroinflammation and oxidative injury, further validation in controlled cortical impact, weight drop, or fluid percussion TBI models would strengthen its relevance to TBI. (Fig. 6).Fig. 6Catalytic mechanism and therapeutic potential of the triM nanozyme. (A) Proposed mechanism by which the triM nanozyme attenuates brain injury through efficient scavenging of reactive oxygen and nitrogen species under physiological conditions. (B) DFT analysis revealing the favorable adsorption and activation of multiple radical species on the triM surface. The calculated interaction energies and optimized adsorption structures support the broad-spectrum catalytic activity of triM toward oxidative and nitrosative stress mediators. Copyright from (Xiaoyu et al., 2019). ACS 2020.Fig. 6 Catalytic mechanism and therapeutic potential of the triM nanozyme. (A) Proposed mechanism by which the triM nanozyme attenuates brain injury through efficient scavenging of reactive oxygen and nitrogen species under physiological conditions. (B) DFT analysis revealing the favorable adsorption and activation of multiple radical species on the triM surface. The calculated interaction energies and optimized adsorption structures support the broad-spectrum catalytic activity of triM toward oxidative and nitrosative stress mediators. Copyright from (Xiaoyu et al., 2019). ACS 2020. The use of a lipopolysaccharide model should therefore be interpreted as evidence for anti-inflammatory and antioxidant potential rather than direct proof of efficacy in mechanical TBI. Lipopolysaccharide induces a strong innate immune response without reproducing impact biomechanics, contusion formation, axonal deformation, hemorrhage, edema evolution, or the spatially heterogeneous BBB disruption typical of trauma. Mechanical TBI models may also involve different treatment windows and biodistribution patterns. Consequently, triM nanozymes should be validated in controlled cortical impact, fluid percussion, weight drop, or blast injury models before their relevance to clinical TBI can be firmly established. Semiconductor nanozymes Semiconductor nanozymes combine catalytic activity with optical, electronic, or imaging properties. Quantum dots and other semiconductor nanomaterials can be engineered to possess enzyme mimicking functions through elemental doping, surface modification, and defect engineering. In the field of TBI, semiconductor nanozymes are particularly attractive because they may integrate therapy and diagnosis within a single platform. Such theranostic systems can not only scavenge reactive species and reduce inflammation but also visualize blood brain barrier disruption, cerebral perfusion abnormalities, and therapeutic responses. This ability is especially valuable because TBI is spatially and temporally heterogeneous, and treatment timing may strongly influence therapeutic efficacy. Liu and colleagues developed a near infrared IIb fluorescent nanozyme by doping manganese atoms into PbS/CdS quantum dots (Liu et al., 2023a). The resulting PbS/Mn:CdS nanozyme emitted at approximately 1670 nm, located in the NIR IIb window. This spectral region offers reduced tissue scattering and low autofluorescence, which allows high resolution in vivo imaging of cerebral microvessels. Manganese doping endowed the quantum dots with antioxidant catalytic activity while maintaining strong fluorescence. After surface modification with oleylamine branched polyacrylic acid and PEG, the hydrodynamic size increased from 19.7 nm to 42.7 nm, and the zeta potential changed from −42.3 mV to −0.564 mV. The PEGylated nanozymes showed good colloidal stability in physiological media and retained 98.2% of their fluorescence intensity after 120 min of 808 nm laser irradiation. The catalytic performance of PbS/Mn:CdS nanozymes was supported by quantitative enzymatic assays. For catalase like activity, the material followed Michaelis Menten kinetics with a Michaelis constant of 62.5 mM and a maximum reaction rate of 0.31 mM min − 1 for hydrogen peroxide. The nanozyme removed superoxide anions with an elimination rate of up to 75% at a manganese concentration of 12 ng μL − 1, and its activity was equivalent to natural superoxide dismutase at 81 U mL − 1. Electron spin resonance measurements further showed that the signal intensity of DMPO superoxide adducts decreased by 87%, while that of DMPO hydroxyl radical adducts decreased by 76%, confirming effective scavenging of both superoxide anions and hydroxyl radicals. In TBI mice, the levels of hydrogen peroxide and malondialdehyde were reduced after nanozyme treatment, and ELISA analysis showed that IL 1 beta, IL 6, and TNF alpha levels decreased by 19.9%, 31.9%, and 25.1%, respectively. The imaging function of this nanozyme is particularly notable. NIR IIb imaging could distinguish cerebral capillaries with an apparent width of 29.1 μm and an exposure time of 20 ms. In TBI mice, dynamic imaging revealed severely impaired perfusion in the injured hemisphere. The perfusion rate of the injured side was 0.07 s − 1, approximately one seventh of the corresponding normal side at 0.51 s − 1. Therapeutically, PEGylated PbS/Mn:CdS nanozymes were administered at 3 h, 5 days, and 10 days after TBI. The ischemic area decreased from 153 mm2 to 36 mm2 on day 5 and nearly disappeared by day 10. In contrast, control quantum dots without ROS scavenging capacity failed to produce comparable perfusion recovery and still showed substantial hypoperfusion after repeated injections. (Fig. 7). (See Fig. 8.)Fig. 7Schematic diagram of intravenous injection of PEGylated PbS/Mn:CdS nanozymes by inhibiting ROS-mediated further BBB disruption. Copyright from (Liu et al., 2023a). Elsevier 2023.Fig. 7Fig. 8Neuroprotective effect of KNC nanozyme in hypoxia–ischemia brain injury. Representative TTC, hematoxylin–eosin, and Nissl-stained brain sections show that KNC treatment preserves neuronal morphology and hippocampal integrity. Quantitative analysis of neuronal density in cortex, CA1, CA3, and DG regions demonstrates significant neuroprotection following 8 ng/mL KNC treatment. These results highlight the potential of KNC to mitigate neuronal loss and support structural recovery after hypoxic–ischemic brain damage. Copyright from (Liu et al., 2023a). Elsevier 2025.Fig. 8 Schematic diagram of intravenous injection of PEGylated PbS/Mn:CdS nanozymes by inhibiting ROS-mediated further BBB disruption. Copyright from (Liu et al., 2023a). Elsevier 2023. Neuroprotective effect of KNC nanozyme in hypoxia–ischemia brain injury. Representative TTC, hematoxylin–eosin, and Nissl-stained brain sections show that KNC treatment preserves neuronal morphology and hippocampal integrity. Quantitative analysis of neuronal density in cortex, CA1, CA3, and DG regions demonstrates significant neuroprotection following 8 ng/mL KNC treatment. These results highlight the potential of KNC to mitigate neuronal loss and support structural recovery after hypoxic–ischemic brain damage. Copyright from (Liu et al., 2023a). Elsevier 2025. This study provides a clear example of how nanozyme therapy can be integrated with real time disease monitoring. The ability to visualize cerebral perfusion and blood brain barrier status allows treatment response to be evaluated dynamically, which is highly relevant for TBI because injury severity and vascular dysfunction vary among individuals. However, the use of Pb and Cd containing quantum dots raises important biosafety concerns. Although PEGylation improved stability and biocompatibility in the preclinical setting, long term metal retention, degradation, and potential heavy metal release must be rigorously addressed before clinical translation. Future semiconductor nanozymes may benefit from the development of less toxic compositions while retaining NIR IIb imaging and catalytic functions. Metal nitrogen carbon nanozymes Metal nitrogen carbon nanozymes have emerged as a highly active class of artificial enzymes inspired by the coordination structure of natural metalloproteins (Xin et al., 2023). In these materials, metal centers or doped metal related sites are embedded within nitrogen doped carbon frameworks. The carbon matrix provides conductivity and structural stability, while nitrogen coordination modulates the electronic structure and creates active sites for redox catalysis (Robert and Meunier, 2022). Compared with conventional metal nanoparticles, metal nitrogen carbon nanozymes can offer higher atomic utilization, tunable catalytic selectivity, and improved stability. In brain injury, this type of nanozyme is promising because it can combine efficient ROS elimination with regulation of disease related molecular pathways (Dong et al., 2022). A recent example is the potassium doped nitrogen carbon nanozyme KNC reported by Dong and colleagues in a hypoxia ischemia brain damage model (Liu et al., 2023a). Although this model is not identical to traumatic brain injury, it shares several key pathological features with TBI, including oxidative stress, neuroinflammation, blood brain barrier dysfunction, lipid peroxidation, and long-term cognitive impairment. KNC was designed as a metal doped nitrogen carbon nanozyme with catalase like and superoxide dismutase like activities. In cell experiments, KNC reduced ROS production in LPS stimulated BV2 microglia and suppressed proinflammatory M1 polarization. The authors used KNC concentrations of 2, 4, and 8 ng mL − 1 in vitro and selected 8 ng mL − 1 for mechanistic intervention experiments involving 12 HETE, a downstream lipid mediator related to ALOX12 activity. In vivo, KNC mitigated hypoxia ischemia induced brain damage. The study reported increased regional cerebral blood flow, reduced proinflammatory microglial activation, decreased astrocyte activation, and improved learning and memory performance after KNC treatment. In the Morris water maze, KNC reduced escape latency during the training phase and improved platform crossing frequency and time spent in the target area during the probe test. The Y maze test further supported recovery of spatial memory. Golgi staining showed that KNC alleviated the loss of dendritic spine density in hippocampal neurons, suggesting protection of synaptic structure. These findings indicate that KNC did not merely reduce acute oxidative injury but also contributed to long term functional recovery. The most distinctive feature of the KNC study is its mechanistic focus on ALOX12 mediated lipid peroxidation. RNA sequencing identified arachidonic acid metabolism and ALOX12 as key changes associated with KNC treatment. Both qPCR and western blot analyses confirmed reduced ALOX12 expression after KNC treatment. Cellular thermal shift assay results suggested an interaction between KNC and ALOX12 in BV2 cells. Functionally, KNC reduced lipid peroxidation and ROS accumulation in LPS stimulated microglia, whereas supplementation with 12 HETE partially weakened the protective effect. In addition, pharmacological inhibition of ALOX12 reduced ROS accumulation and lipid peroxide formation, while ALOX12 overexpression abolished the inhibitory effect of KNC on ROS generation and aggravated lipid peroxidation. These results suggest that KNC regulates oxidative injury not only through direct ROS scavenging but also through suppression of an enzymatic lipid oxidation pathway. This study is valuable for the TBI field because it expands the conceptual role of nanozymes from redox scavengers to pathway regulators. In TBI, lipid peroxidation and ferroptosis are increasingly recognized as important contributors to secondary neuronal death. Therefore, targeting ALOX12 related lipid oxidation may represent a promising direction for next generation nanozymes. Nevertheless, because the study was performed in a hypoxia ischemia model rather than a mechanical trauma model, its conclusions should be translated to TBI with caution. Future studies should test KNC or similar metal nitrogen carbon nanozymes in controlled cortical impact or weight drop TBI models and further examine their effects on ferroptosis markers, blood brain barrier repair, neuronal survival, and long-term behavioral recovery. Taken together, the representative studies discussed above indicate that different nanozyme categories address different therapeutic needs in brain injury. Carbon based nanozymes emphasize biocompatibility, electron transfer regulation, and translational feasibility. Metal based nanozymes provide strong catalytic activity and broad reactive species scavenging, but require careful control of physiological selectivity and long-term safety. Semiconductor nanozymes offer a unique theranostic advantage by integrating catalytic therapy with high resolution imaging of cerebral vasculature and blood brain barrier dysfunction. Metal nitrogen carbon nanozymes provide a bridge between catalytic ROS elimination and molecular pathway regulation, particularly in lipid peroxidation associated injury. For TBI therapy, an ideal nanozyme should not only remove excessive reactive species but also match the pathological characteristics of the injured brain. This includes activity at physiological pH, capacity to regulate both ROS and RNS, ability to accumulate in injured brain regions, minimal long-term toxicity, and potential to modulate downstream mechanisms such as neuroinflammation, ferroptosis, blood brain barrier disruption, and synaptic injury. Current evidence suggests that nanozyme development is moving from simple antioxidant replacement toward rationally designed catalytic nanomedicine. The next stage of this field will likely depend on integrating catalytic efficiency, disease specific targeting, mechanistic pathway regulation, and clinically feasible manufacturing within a single therapeutic platform. (Table 3).Table 3Representative nanozymes for TBI and related brain injury models.NanozymeTypeModelMain activityMajor findingsO-NZCarbonTBISOD, GPxImproved survival and cognitioncOACCarbonmTBISOD-likeRestored cerebral perfusiontriMMetalBrain injuryMulti-enzymeReduced neuroinflammationPbS/Mn:CdSSemiconductorTBICAT, SODImaging-guided therapyKNCM-N-CHIBDCAT, SODALOX12 inhibition Table 3Representative nanozymes for TBI and related brain injury models.NanozymeTypeModelMain activityMajor findingsO-NZCarbonTBISOD, GPxImproved survival and cognitioncOACCarbonmTBISOD-likeRestored cerebral perfusiontriMMetalBrain injuryMulti-enzymeReduced neuroinflammationPbS/Mn:CdSSemiconductorTBICAT, SODImaging-guided therapyKNCM-N-CHIBDCAT, SODALOX12 inhibition Representative nanozymes for TBI and related brain injury models. Clinical relevance also depends strongly on therapeutic timing. Among the representative systems reviewed here, PEG cOAC is notable because it was administered intravenously at 80 min after mild TBI combined with hemorrhagic hypotension and resuscitation, a design that more closely resembles delayed emergency treatment than immediate prophylaxis. The PbS/Mn:CdS nanozyme was administered at 3 h, 5 days, and 10 days after TBI, supporting the concept of delayed and repeated treatment guided by vascular imaging. In contrast, O-NZ efficacy has mainly been evaluated in acute small animal TBI paradigms, and the clinically realistic limits of delayed dosing remain to be defined. triM was tested in a lipopolysaccharide neuroinflammation model rather than mechanical trauma, and KNC was tested in hypoxia ischemia brain damage; therefore, their therapeutic timing cannot be directly extrapolated to TBI. Future studies should explicitly report time from injury to treatment, compare immediate versus delayed dosing, and test treatment windows compatible with prehospital transport, emergency evaluation, neurosurgical care, and intensive care workflows. Current challenges for clinical translation Although nanozymes have shown encouraging therapeutic potential in experimental models of TBI and related brain injuries, their clinical translation remains at an early stage. Current studies demonstrate that nanozymes can reduce oxidative stress, suppress neuroinflammation, protect the blood brain barrier, and improve neurological outcomes. However, most available evidence is still derived from small animal models, and many key issues remain unresolved. These include efficient delivery across the blood brain barrier, long term biosafety, standardized evaluation of catalytic activity, scalable production, and disease specific mechanism-oriented design (Liu et al., 2023a; Liu et al., 2023b). Addressing these challenges will be essential for transforming nanozymes from experimental antioxidants into clinically applicable catalytic nanomedicines for TBI. A key translational concern is whether current experimental models adequately represent human TBI heterogeneity. Controlled cortical impact, fluid percussion, weight drop, blast injury, and hypoxia ischemia models each reproduce selected pathological features, but none captures the full spectrum of human injury, which may include mixed focal and diffuse damage, skull fracture, hemorrhage, polytrauma, hypoxia, hypotension, age related vulnerability, sex differences, and comorbid disease. Many nanozyme studies rely on young healthy rodents, early treatment, short follow up, and single injury mechanisms, which may overestimate efficacy. Future studies should therefore include model diversity, delayed dosing, clinically relevant supportive care, sex and age stratification, imaging or biomarker based severity grading, and long term behavioral endpoints. Efficient BBB delivery Efficient delivery to injured brain tissue remains one of the most critical barriers for nanozyme therapy in TBI. The blood brain barrier tightly regulates the transport of molecules and particles between the circulation and the central nervous system. Under physiological conditions, this barrier strongly restricts the entry of most nanomaterials into the brain. After TBI, the blood brain barrier is often transiently disrupted because of mechanical vascular damage, oxidative stress, inflammatory signaling, and tight junction degradation. This pathological opening may provide a temporary window for nanozyme accumulation within injured regions. However, the extent, location, and duration of blood brain barrier disruption are highly heterogeneous among different injury severities, animal models, and disease stages. Therefore, passive accumulation based only on barrier leakage may be unreliable. Future nanozyme design should move beyond passive delivery and incorporate active or responsive delivery strategies. Surface modification with ligands targeting transferrin receptors, low density lipoprotein receptors, insulin receptors, or cell adhesion molecules may enhance receptor mediated transport across the blood brain barrier. Peptide based targeting motifs, cell membrane coatings, exosome mimetic carriers, and immune cell mediated delivery systems may also improve lesion specific accumulation. In addition, the injured brain microenvironment possesses several pathological features, including elevated ROS levels, acidic local regions, inflammatory enzymes, and abnormal matrix metalloproteinase activity. Nanozymes responsive to these pathological cues could remain relatively inert in normal tissues but become activated or retained in injured brain regions. The timing of administration is another important issue. The blood brain barrier is not uniformly open throughout the disease course. In the acute phase, vascular rupture and barrier leakage may promote nanoparticle entry, whereas in the subacute and chronic phases, barrier recovery may reduce passive delivery. Conversely, delayed treatment may be clinically more realistic, because many TBI patients do not receive therapy immediately after injury. Therefore, future studies should define the therapeutic time window of nanozymes and determine whether repeated administration, sustained release systems, or local delivery approaches are required. Imaging guided delivery represents a particularly promising direction. Fluorescent, magnetic resonance, photoacoustic, or radionuclide labeled nanozymes could be used to monitor brain accumulation, vascular leakage, and therapeutic response in real time. For example, NIR IIb fluorescent nanozymes have demonstrated the ability to dynamically monitor blood brain barrier status and cerebral perfusion in TBI models. This type of theranostic platform may help identify the optimal treatment window and reduce unnecessary dosing. Nevertheless, imaging capable nanozymes must balance diagnostic performance with safety, especially when heavy metal elements or persistent inorganic cores are involved. Overall, future BBB delivery strategies should satisfy four requirements. First, nanozymes should reach injured brain regions efficiently after systemic administration. Second, they should avoid excessive accumulation in healthy brain and peripheral organs. Third, their delivery should match the dynamic pathological stage of TBI. Fourth, brain accumulation should be quantitatively evaluated using reliable imaging, biodistribution, and pharmacokinetic analyses. Without solving the delivery problem, even highly active nanozymes may fail to achieve meaningful clinical efficacy. A clinically realistic delivery strategy should be linked to the care pathway of TBI patients. Treatments that require administration before injury or within only a few minutes after trauma are unlikely to translate broadly, except in highly controlled military or surgical settings. More practical windows include early emergency treatment within 1 to 3 h, delayed treatment after imaging and stabilization, repeated dosing during the subacute inflammatory phase, and local or sustained release approaches during surgery or rehabilitation. Therefore, nanozyme studies should predefine clinically meaningful time windows and evaluate whether efficacy persists when treatment is delayed. Long term biosafety Long term biosafety is another major challenge for nanozyme translation. Because nanozymes are designed to catalyze redox reactions in biological environments, their safety assessment should be more comprehensive than that of inert nanoparticles. Conventional evaluations, such as short-term cell viability, body weight monitoring, hematology, serum biochemistry, and hematoxylin and eosin staining, are necessary but insufficient. For TBI therapy, nanozymes may interact with neurons, microglia, astrocytes, endothelial cells, peripheral immune cells, and clearance organs. Therefore, both central nervous system safety and systemic safety must be examined over extended periods. The composition of nanozymes strongly influences their biosafety profile. Carbon based nanozymes may show favorable biocompatibility and lower metal related toxicity, but their degradation, persistence, and possible inflammatory responses remain to be clarified. Noble metal nanozymes often possess high catalytic activity, but long-term retention in the liver, spleen, kidney, or brain may raise concerns. Semiconductor quantum dot nanozymes can provide excellent imaging functions, but the presence of elements such as leads or cadmium requires careful evaluation of metal ion release, organ accumulation, and delayed toxicity. Metal nitrogen carbon nanozymes may offer improved atomic utilization and catalytic selectivity, but their metabolic fate and interaction with endogenous proteins require further study. An ideal nanozyme for TBI should either be biodegradable into nontoxic products or be efficiently cleared from the body after completing its therapeutic function. Size is a critical determinant of clearance. Ultrasmall nanozymes may undergo renal filtration, whereas larger particles are more likely to accumulate in the mononuclear phagocyte system. Surface charge, hydrophilicity, protein corona formation, and PEGylation also affect circulation, tissue distribution, immune recognition, and excretion. Therefore, safety evaluation should include quantitative pharmacokinetic and biodistribution studies, preferably using radiolabeling, elemental analysis, fluorescence imaging, or mass spectrometry. Available biosafety evidence remains uneven among nanozyme classes. Ultrasmall carbon nanozymes such as O-NZ show encouraging renal clearance, with nearly 80% reported clearance within 12 h, suggesting a potential advantage for reducing long term retention. Carbon activated charcoal nanozymes may benefit from medically familiar source materials, but their biodegradation, chronic immune effects, and repeated dose safety remain insufficiently defined. Noble metal nanozymes can be catalytically potent but may persist in the liver, spleen, kidney, or brain, requiring elemental retention and chronic toxicity studies. Semiconductor nanozymes with heavy metal components provide powerful imaging functions, but possible Pb or Cd ion release is a major translational concern. Metal nitrogen carbon nanozymes may offer atomically dispersed active sites, yet their degradation products, protein corona effects, and long term neuroimmune interactions still require systematic investigation. In the central nervous system, special attention should be paid to neurotoxicity and immunotoxicity. Nanozymes that excessively suppress ROS may interfere with physiological redox signaling, synaptic plasticity, and immune defense. ROS are not only damaging molecules but also participate in cellular signaling, vascular regulation, and repair processes. Thus, indiscriminate or prolonged ROS elimination may produce unexpected effects. Future studies should determine whether nanozyme treatment alters neurogenesis, synaptic remodeling, glial homeostasis, learning and memory, or emotional behavior during long term recovery. Another concern is the potential pro-oxidant activity of nanozymes under certain conditions. Some nanozymes may exhibit antioxidant activity in one microenvironment but peroxidase like or oxidase like activity in another. This catalytic plasticity can be useful for cancer therapy but may be harmful in injured brain tissue. Therefore, nanozymes intended for TBI should be tested under physiologically relevant conditions, including neutral pH, high ROS concentrations, inflammatory media, hypoxia, serum protein exposure, and brain homogenate systems. Long term safety should also be evaluated after repeated dosing, because TBI patients may require sustained or multiple treatments. Future biosafety studies should include standardized acute, subacute, and chronic toxicity protocols. These should incorporate behavioral testing, neurohistology, glial activation markers, organ pathology, inflammatory cytokines, oxidative stress indicators, reproductive toxicity when appropriate, and clearance analysis. For materials containing potentially toxic elements, ion release and elemental retention should be monitored for weeks to months. Only through rigorous long term biosafety evaluation can nanozymes move toward clinical development. Standardization of nanozyme activity evaluation A major obstacle in the nanozyme field is the lack of standardized methods for activity evaluation. Different studies often use different substrates, buffer systems, pH values, temperatures, reaction times, detection probes, and data normalization methods. As a result, catalytic performance is difficult to compare across materials and laboratories. This problem is particularly relevant for TBI therapy because enzyme like activity measured under artificial conditions may not reflect catalytic function in the injured brain. For antioxidant nanozymes, the most commonly evaluated activities include superoxide dismutase like, catalase like, glutathione peroxidase like, peroxidase like, and reactive nitrogen species scavenging activities. However, assays for these activities vary widely. For example, superoxide scavenging may be evaluated using WST based methods, nitroblue tetrazolium reduction, electron spin resonance, or xanthine oxidase systems. Catalase like activity may be assessed by dissolved oxygen generation, hydrogen peroxide depletion, or colorimetric probes. Glutathione peroxidase like activity often involves coupled reactions with glutathione and hydrogen peroxide. Each assay has limitations, and interference from nanoparticle absorbance, fluorescence, surface adsorption, or catalytic side reactions may produce misleading results. Future studies should report enzyme kinetic parameters in a more systematic manner. These should include the Michaelis constant, maximum reaction velocity, catalytic constant when possible, specific activity normalized to mass, surface area, particle number, or active site concentration, and stability under biologically relevant conditions. Reporting only percentage ROS scavenging is insufficient because it depends strongly on substrate concentration, incubation time, and detection method. For nanozymes with multiple activities, the balance among different catalytic functions should also be evaluated. A material with high peroxidase like activity may not be suitable for TBI if it generates additional radicals under physiological conditions. The biological relevance of activity assays also needs improvement. Many nanozymes show high activity in acidic buffers or simplified chemical systems, but TBI occurs in a complex biological environment containing proteins, salts, lipids, metabolites, inflammatory mediators, and endogenous antioxidants. Protein corona formation may mask active sites or change catalytic selectivity (Cai et al., 2022). Local pH, oxygen concentration, and substrate availability may also influence catalytic behavior. Therefore, activity should be evaluated not only in simple buffers but also in serum containing media, cerebrospinal fluid mimetic solutions, brain tissue homogenates, and cell based oxidative stress models. Another important issue is the standardization of disease related endpoints. For TBI studies, nanozyme efficacy should not be judged only by ROS probe fluorescence. A more convincing evaluation should include multiple levels of evidence, such as biochemical ROS and RNS markers, lipid peroxidation products, mitochondrial function, inflammatory cytokines, blood brain barrier integrity, neuronal survival, lesion volume, cerebral perfusion, and behavioral recovery. The field would benefit from a consensus reporting framework that links catalytic activity with biological function (Zhang et al., 2023b). Structure activity relationship studies are also essential for standardization. The cOAC study provides a useful example by correlating synthesis conditions, particle size, oxygen functional groups, electrochemical properties, and antioxidant bioactivity. Similar approaches should be extended to other nanozyme categories. For metal based nanozymes, valence state, coordination environment, crystal facet, and metal ratio should be reported. For carbon based nanozymes, defect density, heteroatom content, oxygen functionality, surface charge, and electron transfer properties should be characterized. For semiconductor nanozymes, band structure, dopant distribution, fluorescence stability, and ion release should be included. Only by connecting physicochemical parameters with catalytic and biological outcomes can rational nanozyme design become possible. Specific design principles and benchmarks are needed for next generation TBI nanozymes. Candidate materials should demonstrate SOD like, catalase like, or GPx like activity under physiological pH and biologically relevant substrate concentrations; maintain activity in serum, cerebrospinal fluid mimetic media, and brain homogenates; avoid pro-oxidant behavior under inflammatory conditions; and show quantitative brain accumulation, retention, and clearance. Efficacy evaluation should include ROS/RNS markers, lipid peroxidation products, inflammatory cytokines, BBB integrity, lesion volume, cerebral perfusion, neuronal survival, and motor and cognitive recovery. Translationally, reports should provide dosing route, therapeutic time window, pharmacokinetics, biodistribution, sex and age information, randomization and blinding, and comparison with clinically used or clinically tested agents. Such standardized criteria would make cross-study comparison more meaningful and help identify materials with genuine clinical potential. Large scale manufacturing and GMP production Large scale manufacturing is a key requirement for clinical translation but remains underdeveloped in the nanozyme field. Many nanozymes are synthesized using laboratory scale methods that are difficult to reproduce at industrial scale. These methods may involve harsh oxidants, high temperature reactions, organic solvents, complex purification steps, or low yield procedures. For clinical use, manufacturing processes must be scalable, reproducible, cost effective, and compatible with regulatory requirements. Batch to batch consistency is particularly important for nanozymes because small changes in size, morphology, surface chemistry, oxidation state, or dopant distribution may significantly alter catalytic activity and biological behavior. Therefore, manufacturing should be guided by critical quality attributes. These may include particle size distribution, hydrodynamic diameter, zeta potential, elemental composition, surface functional groups, active site density, catalytic activity, endotoxin level, sterility, residual solvent content, and colloidal stability. Each parameter should have an acceptable range linked to biological performance. The cOAC platform (McHugh et al., 2024) provides an instructive example for translational design. It uses coconut shell activated charcoal from a medical grade source and examines how oxidation conditions affect particle size, chemical composition, electrochemical behavior, and antioxidant bioactivity. This type of process structure property performance analysis is highly valuable because it allows manufacturing parameters to be connected with therapeutic function. The use of medically familiar source materials may also facilitate regulatory acceptance compared with more exotic or poorly characterized nanomaterials. However, even for carbon-based systems, harsh oxidative synthesis must be carefully controlled to ensure safety, reproducibility, and environmental compatibility. Good manufacturing practice production requires more than scaling up synthesis. It also requires validated purification, sterile formulation, storage stability, quality control, and release testing. Nanozymes intended for intravenous administration must be free of endotoxin, aggregates, and toxic impurities. Their catalytic activity should remain stable during storage and after exposure to physiological media. Lyophilized formulations, cryoprotectants, or buffer optimization may be needed to preserve activity. For PEGylated nanozymes, the stability of PEG conjugation and the risk of anti-PEG immune responses should also be considered. Regulatory classification may be complex because nanozymes combine features of drugs, biologically active catalysts, and nanomaterials. If a nanozyme also carries imaging capability or drug loading function, it may be considered a combination product. This increases the requirements for pharmacology, toxicology, chemistry manufacturing control, and clinical trial design. Therefore, early communication with regulatory agencies and adoption of quality by design principles will be important for future development. From an industrial perspective, future nanozyme platforms should be designed with manufacturability in mind from the beginning. Simple synthesis, abundant raw materials, mild reaction conditions, high yield, scalable purification, and robust quality control will be major advantages. Highly sophisticated nanozymes may show excellent performance in animal models but may fail to translate if their production is too complex or poorly reproducible. Therefore, translational potential should become a core criterion in nanozyme design, not an afterthought. Multifunctionality also creates important trade offs. Combining antioxidant catalysis, active targeting, imaging, drug loading, and responsive release can improve therapeutic precision, but each added function increases synthetic complexity, quality control burden, analytical requirements, and regulatory uncertainty. Highly complex platforms may be difficult to reproduce across batches, scale under good manufacturing practice, sterilize without activity loss, or classify within existing drug and device frameworks. Therefore, multifunctional nanozymes should be designed according to a minimal sufficient function principle: additional modules should be retained only when they improve delivery, safety, mechanistic validation, or therapeutic efficacy beyond what a simpler catalytic platform can achieve. Future perspectives: mechanism oriented nanozyme design Early nanozyme studies in TBI mainly focused on broad ROS elimination. While this strategy is biologically reasonable, it may be insufficient because TBI involves multiple interconnected pathological pathways, including oxidative stress, neuroinflammation, mitochondrial dysfunction, blood brain barrier disruption, ferroptosis, excitotoxicity, synaptic injury, and vascular dysfunction. Future nanozymes should be designed not only as ROS scavengers but also as regulators of disease relevant mechanisms. Mechanism oriented design begins with identifying the dominant pathological processes at specific stages of TBI. In the hyperacute and acute phases, excessive superoxide, hydrogen peroxide, hydroxyl radicals, nitric oxide, and peroxynitrite contribute to mitochondrial injury, vascular dysfunction, and neuronal death. During the subacute phase, microglial activation, astrocyte reactivity, cytokine production, and blood brain barrier remodeling become increasingly important. In the chronic phase, persistent inflammation, synaptic dysfunction, white matter degeneration, and neurodegenerative processes may dominate. Different nanozymes may be needed for different stages, or a single nanozyme may need stage responsive catalytic functions. Several mechanisms are particularly relevant for future design. First, the Nrf2 and HO 1 pathway is an endogenous antioxidant defense system and has been implicated in neuroprotection after brain injury. Nanozymes that both reduce ROS and activate endogenous antioxidant signaling may produce more durable therapeutic effects than direct scavenging alone. Second, inflammatory pathways such as NF kappa B and NLRP3 are closely linked to oxidative stress. Nanozymes capable of interrupting ROS driven inflammatory activation may reduce secondary injury more effectively. Third, lipid peroxidation and ferroptosis are increasingly recognized as important drivers of neuronal loss after TBI. Nanozymes that suppress lipid peroxide accumulation or regulate enzymes such as ALOX12 may provide a new therapeutic direction. The KNC study illustrates the value of mechanism oriented nanozyme design. KNC was shown to reduce ROS production and microglial M1 polarization, but more importantly, it was linked to ALOX12 mediated lipid peroxidation. This suggests that nanozymes can function as pathway modulators rather than simple radical scavengers. Such a concept is highly relevant for TBI, where oxidative stress interacts with inflammatory and metabolic pathways. Future studies should explore whether nanozymes can modulate ferroptosis regulators such as GPX4, ACSL4, SLC7A11, FSP1, and iron metabolism proteins in mechanical TBI models. Another future direction is cell specific nanozyme design. Neurons, microglia, astrocytes, endothelial cells, and infiltrating immune cells have different redox states and pathological roles after TBI. A nanozyme that protects neurons may not necessarily suppress harmful microglial activation, and a material that enters endothelial cells may be more effective for blood brain barrier repair. Therefore, targeting specific cell populations could increase therapeutic precision. This may be achieved by surface ligands, biomimetic coatings, or local microenvironment responsive activation. Mechanism oriented design should also consider redox balance rather than complete ROS elimination. Physiological ROS participate in cell signaling, angiogenesis, immune defense, and tissue repair. Excessive suppression of ROS may impair recovery. Therefore, future nanozymes should ideally restore redox homeostasis rather than indiscriminately remove all reactive species. Catalytic selectivity, activity under physiological pH, and self-limiting behavior will become important design principles. Finally, integration of computational modeling, high throughput screening, omics analysis, and artificial intelligence may accelerate mechanism oriented nanozyme development. Density functional theory can help predict active sites and catalytic pathways. Transcriptomics, proteomics, and metabolomics can identify disease relevant pathways affected by nanozyme treatment. Artificial intelligence may assist in correlating composition, structure, catalytic activity, biodistribution, and therapeutic outcome. Through these approaches, nanozyme design may evolve from empirical material screening toward rational development of precision catalytic nanomedicine. In summary, the future of nanozyme therapy for TBI depends on solving delivery, safety, standardization, manufacturing, and mechanism related challenges. The most promising nanozymes will not simply possess high catalytic activity in chemical assays. They will need to reach injured brain tissues efficiently, act under physiologically relevant conditions, regulate disease specific mechanisms, show long term safety, and be manufactured reproducibly under clinically acceptable standards. Achieving these goals will require close collaboration among materials scientists, neuroscientists, pharmacologists, clinicians, and regulatory experts. Conclusions TBI is a highly complex neurological disorder characterized by primary mechanical damage and progressive secondary injury. Although primary injury occurs immediately and is difficult to reverse, secondary injury provides a critical therapeutic window for intervention. Oxidative stress, neuroinflammation, blood brain barrier disruption, mitochondrial dysfunction, lipid peroxidation, ferroptosis, and regulated neuronal death are closely interconnected during this process. Among these pathological events, redox imbalance plays a central role because excessive reactive oxygen species and reactive nitrogen species can directly damage neural cells and amplify inflammatory, vascular, and metabolic dysfunction. Therefore, restoring redox homeostasis represents a rational and promising strategy for limiting secondary brain injury and improving neurological recovery. Nanozymes have emerged as a new class of catalytic nanomedicines with considerable potential for TBI therapy. Compared with conventional antioxidants and natural enzymes, nanozymes offer several distinctive advantages, including higher stability, tunable catalytic activity, multifunctional integration, and the ability to repeatedly convert harmful reactive species into less toxic products (Liao et al., 2024a; Liao et al., 2024b; Liao et al., 2025b; Zhang et al., 2025c). Recent studies have demonstrated that different nanozyme platforms can target multiple pathological aspects of brain injury. Carbon based nanozymes show favorable biocompatibility, efficient electron transfer, and translational potential. Metal based nanozymes provide strong catalytic activity and broad reactive species scavenging capacity. Semiconductor nanozymes integrate antioxidant therapy with high resolution imaging, enabling dynamic monitoring of blood brain barrier dysfunction and cerebral perfusion. Metal nitrogen carbon nanozymes provide tunable active sites and may regulate disease related pathways such as lipid peroxidation and inflammatory activation. The representative studies discussed in this review illustrate the rapid evolution of nanozyme design for brain injury treatment. Oligomeric carbon nanozymes demonstrate that ultrafast electron transfer can markedly enhance antioxidant catalytic efficiency and improve survival and cognitive outcomes after acute brain trauma. Oxidized activated charcoal nanozymes highlight the importance of process, structure, property, and performance relationships for translational optimization. Trimetallic nanozymes emphasize catalytic selectivity and activity under physiological conditions, which are essential for central nervous system applications. NIR IIb fluorescent nanozymes show that catalytic therapy can be combined with real time imaging guidance. Potassium doped nitrogen carbon nanozymes further suggest that nanozymes may act as pathway regulators by suppressing ALOX12 associated lipid peroxidation and neuroinflammation. Together, these studies indicate that nanozyme research is moving beyond simple ROS elimination toward rational, multifunctional, and mechanism oriented therapeutic design. Despite these promising advances, several critical challenges must be addressed before nanozymes can be translated into clinical therapy for TBI. Efficient delivery across the blood brain barrier remains a major obstacle, especially because barrier disruption after TBI is spatially heterogeneous and temporally dynamic. Long term biosafety also requires rigorous evaluation, particularly for nanozymes containing noble metals, heavy metals, or persistent inorganic cores. Standardized methods for measuring enzyme like activity are urgently needed to allow meaningful comparison across different materials and laboratories. In addition, large scale manufacturing, batch to batch reproducibility, sterile formulation, storage stability, and good manufacturing practice production should be considered early during nanozyme development rather than after efficacy has been demonstrated. Future nanozyme design should focus on restoring redox balance rather than indiscriminately eliminating all reactive species. Physiological levels of reactive species participate in vascular regulation, immune signaling, synaptic plasticity, and tissue repair. Therefore, the most desirable nanozymes for TBI should exhibit catalytic selectivity, activity under physiological conditions, and responsiveness to disease microenvironments. Mechanism oriented design will be particularly important. Future nanozymes may be engineered to regulate specific pathological pathways, including Nrf2 and HO 1 antioxidant signaling, NF kappa B and NLRP3 mediated inflammation, mitochondrial dysfunction, blood brain barrier repair, ferroptosis, and ALOX12 mediated lipid peroxidation. Such designs may enable nanozymes to function not only as antioxidant catalysts but also as regulators of the secondary injury network. In addition, the field should move toward integrated therapeutic systems. Imaging capable nanozymes may help identify the optimal treatment window and guide individualized therapy. Biomimetic coatings, receptor targeting ligands, exosome inspired delivery systems, and local sustained release platforms may improve lesion accumulation and reduce systemic exposure. Combination strategies involving nanozymes and neuroprotective drugs, anti-inflammatory agents, stem cell derived vesicles, or rehabilitation interventions may further enhance therapeutic efficacy. Advanced tools such as transcriptomics, proteomics, metabolomics, computational modeling, and artificial intelligence may accelerate the discovery of structure activity relationships and help identify disease specific catalytic mechanisms. In conclusion, nanozymes provide a promising and rapidly developing strategy for the treatment of TBI. Their ability to integrate catalytic antioxidant activity, microenvironment responsiveness, biological pathway regulation, and imaging guidance makes them highly suitable for targeting the multifactorial nature of secondary brain injury. However, successful translation will depend on solving key problems related to delivery, safety, standardization, manufacturing, and mechanistic validation. With continued advances in materials science, neuroscience, pharmacology, and clinical translation, nanozyme based catalytic nanomedicine may offer new opportunities for improving outcomes in patients with TBI and other neurological disorders driven by oxidative stress. CRediT authorship contribution statement Yi Ma: Investigation. Xialio Tan: Writing – original draft, Conceptualization. Xinyue Chen: Writing – original draft, Formal analysis. Hongbin Zang: Software, Project administration. Zhe Li: Validation, Conceptualization. Xin Deng: Writing – review & editing, Formal analysis. Jinqu Hu: Writing – review & editing, Funding acquisition. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.